Kyleena (Levonorgestrel)

Levonorgestrel released from the intrauterine system binds to progesterone receptors in the endometrium, cervical mucus and the hypothalamic‑pituitary axis. This suppresses ovulation, thickens cervical mucus to block sperm entry, and induces endometrial atrophy, creating conditions that prevent fertilisation and implantation.

The dose of levonorgestrel in Kyleena is fixed at 19.5 mg within the intrauterine system. The prescriber determines suitability and timing of insertion; no patient‑adjustable dosing is required.

Kyleena is contraindicated in pregnancy (Category X) and must not be inserted in a pregnant woman. For breastfeeding women, the device may be used after careful risk‑benefit assessment, as levonorgestrel exposure through breast milk is minimal, but clinicians should monitor the infant.

To order Kyleena, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with copper IUDs, Kyleena releases levonorgestrel, which can reduce menstrual bleeding and cause fewer cramping episodes. Its hormone‑based mechanism offers contraceptive efficacy similar to other levonorgestrel‑releasing systems but with a lower hormone dose than some alternatives, resulting in a favorable side‑effect profile for many users.

Kyleena should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperature fluctuations. Handling should be performed by trained healthcare professionals during insertion and removal procedures.

Kyleena is inserted by a qualified clinician into the uterine cavity through the cervical canal using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions. Once placed, the device remains effective for up to five years without the need for daily action by the user.

The most serious risks include uterine perforation during insertion, expulsion of the device, and pelvic inflammatory disease, all of which require prompt medical evaluation. Rarely, ectopic pregnancy can occur if fertilisation happens despite the device. Patients should seek immediate care for severe abdominal pain, abnormal bleeding or signs of infection.

Kyleena is contraindicated in women who are pregnant, have active pelvic infections, untreated cervical or uterine cancer, unexplained vaginal bleeding, or severe uterine abnormalities such as large fibroids. Women with a history of thrombosis should discuss risks with their clinician before use.